Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. [PDF]
Eur J Cancer, 2020 Campbell K +9 more
europepmc +3 more sources
A Pilot Study of Relating MYCN-Gene Amplification with Neuroblastoma-Patient CT Scans [PDF]
arXiv, 2022 Neuroblastoma is one of the most common cancers in infants, and the initial diagnosis of this disease is difficult. At present, the MYCN gene amplification (MNA) status is detected by invasive pathological examination of tumor samples. This is time-consuming and may have a hidden impact on children.
Zihan Zhang +3 more
openalex +3 more sources
The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification [PDF]
International Journal of Cancer, 2009 Dirk Geerts +9 more
openalex +2 more sources
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors [PDF]
, 2015 Dysregulation of the cell cycle and cyclin-dependent kinases (cdks) is a hallmark of cancer cells. Intervention with cdk function is currently evaluated as a therapeutic option in many cancer types including neuroblastoma (NB), a common solid tumor of ...
Eggert, Angelika +8 more
core +11 more sources
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. [PDF]
Int J Mol Sci, 2023 Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB's mutation landscape, optimizing individualized therapies is still challenging.
De Rosa P +8 more
europepmc +3 more sources
MYCN gene amplification in rhabdomyosarcoma [PDF]
Cancer, 1994 Amplification of the MYCN oncogene, formerly known as N-myc, has been seen in several malignant tumors, particularly neuroblastoma, where its association with a poor clinical outcome is the clearest example of a clinically relevant oncogene mutation in any human cancer.The incidence and clinical significance of MYCN amplification in rhabdomyosarcoma ...
Paul S. Thorner +4 more
openaire +3 more sources
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
BMC Pediatrics, 2020 Background Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. Methods The expression profiles of MYCN associated genes were identified
Haiwei Wang +4 more
doaj +1 more source
P11.03 Next generation sequencing-identified IDH-1, ATRX, TP53 mutation and MYCN amplification in glioblastoma with primitive neuroectodermal tumor-like feature and extensive subarachnoid spread: a case report [PDF]
Neuro Oncol, 2019 Lee K, Gheeyoung C.
europepmc +3 more sources
MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
Cancers, 2023 Cancer is a disease caused by (epi)genomic and gene expression abnormalities and characterized by metabolic phenotypes that are substantially different from the normal phenotypes of the tissues of origin. Metabolic reprogramming is one of the key features of tumors, including those established in the human nervous system.
Marialena Pouliou +6 more
openaire +2 more sources